Rapid suppression of neuropathic pain and somatosensory hyperactivity by nano-formulated cannabidiol
Cell Chemical Biology · 2025-11 · 32 (11) · 1412-1428.e5
DOI: 10.1016/j.chembiol.2025.10.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Chemical Biology, 2025-11. Verfasst von Jingyu Feng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, US…. Hauptthemen laut MEDLINE: Cannabidiol, Neuralgia, Analgesics, Nanoparticles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: NCCIH NIH HHS, National Institutes of Health, National Center for Complementary and Integrative Health.
Abstract (Originalsprache)
Cannabis-derived compounds, particularly the non-psychoactive cannabidiol (CBD), hold significant potential for pain management. However, CBD's hydrophobicity limits systemic brain delivery, constraining both its therapeutic efficacy and mechanistic investigation. Here, we present an inclusion-complex-enhanced nano-micelle formulation (CBD-IN) that significantly improves systemic absorption and elevates brain CBD levels. A single dose of CBD-IN fully suppresses allodynia and hyperalgesia in a mouse model of neuropathic pain, without impairing normal sensorimotor or cognitive functions. This rapid and robust analgesic effect enables in-depth investigation of underlying neural mechanisms. Activity-dependent genetic mapping reveals that CBD-IN selectively reduces allodynia-associated neuronal activation across the somatosensory system. Complementary calcium imaging in spinal nociceptive and somatosensory corticospinal neurons further demonstrates pathophysiological state-dependent neural suppression by CBD. These results demonstrate that nano-formulated CBD delivers rapid and effective analgesia by selectively suppressing pathological hyperactivity throughout the somatosensory system, offering a promising therapeutic strategy for neuropathic pain and other disorders involving circuit-level disinhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA.
- F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology and Ophthalmology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.
- F.M. Kirby Neurobiology Center, Boston Children's Hospital, and Department of Neurology and Ophthalmology, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA. Electronic address: zhigang.he@childrens.har…
- Department of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA. Electronic address: kuanhong_wang@urmc.rochester.edu.
Förderung
- NCCIH NIH HHS
- National Institutes of Health
- National Center for Complementary and Integrative Health
Zitieren
APA
Feng, J., Page, J., Chung, L., He, Z., & Wang, K. H. (2025). Rapid suppression of neuropathic pain and somatosensory hyperactivity by nano-formulated cannabidiol. Cell Chemical Biology, 32(11), 1412-1428.e5. https://doi.org/10.1016/j.chembiol.2025.10.005
Vancouver
Feng J, Page J, Chung L, He Z, Wang KH. Rapid suppression of neuropathic pain and somatosensory hyperactivity by nano-formulated cannabidiol. Cell Chemical Biology. 2025;32(11):1412-1428.e5. doi:10.1016/j.chembiol.2025.10.005
BibTeX
@article{Feng2025,
author = {Feng, Jingyu and Page, Jessica and Chung, Leeyup and He, Zhigang and Wang, Kuan Hong},
title = {Rapid suppression of neuropathic pain and somatosensory hyperactivity by nano-formulated cannabidiol},
journal = {Cell Chemical Biology},
year = {2025},
volume = {32},
number = {11},
pages = {1412--1428.e5},
doi = {10.1016/j.chembiol.2025.10.005}
}
EUVIMED